64Cu-SAR-BBN & 67Cu-SAR-BBN target GRPR in metastatic castrate-resistant prostate cancer for patients ineligible for 177Lu-PSMA-617.

[God_Loves_Me]

I am NOT promoting clinical trials; I am here to learn about trials and related questions.

Has anyone here participated in these clinical trials?

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) (COMBAT)

clinicaltrials.gov/study/NC...

Questions -

I have never heard of Gastrin Releasing Peptide Receptor (GRPR) from my MO, and it is constantly discussed related to PSMA METS. Now, what does this drug do?

How do I compare with other drugs like docetaxel and pluvicto?

Please share anything that you know about.

[Tall_Allen]

I wrote the following in 2017:

prostatecancer.news/2017/03...

I know that Andrei Iagaru at Stanford has been investigating similar radio-theranostics:

jnm.snmjournals.org/content...

The worry is pancreas toxicity, but it seems to be acceptable.

[God_Loves_Me in reply to Tall_Allen]

Learning questions -

- Does this treatment lower PSA?

- Can measure improvement from PET Scan? If Not, then what are other reports I should request for?

- Is there anything that you would like to share that help me to decide whether to participate in clinical trials or not

[Tall_Allen in reply to God_Loves_Me]

" Does this treatment lower PSA?" They expect it will. One of the primary outcomes is the proportion of participants with ≥50% decline in PSA

"Can measure improvement from PET Scan? If Not, then what are other reports I should request for?" They will measure radiographic response. They will tell you what is needed.

"Is there anything that you would like to share that help me to decide whether to participate in clinical trials or not" You did one, didn't you? So you know about the level of care you get. I'm also hopeful about this one:

clinicaltrials.gov/study/NC...

[j-o-h-n]

Gastrin Releasing Peptide Receptor (GRPR) Now, what does this drug do?

How to compare with other drugs like docetaxel and pluvicto?

ChatGPT said:

Gastrin-Releasing Peptide Receptor (GRPR) is not a drug, but rather a G-protein-coupled receptor that plays a role in various physiological processes, including cancer growth, especially in prostate cancer, lung cancer, and gastrointestinal tumors. However, drugs or radioligands targeting GRPR are being developed for both diagnostic and therapeutic purposes, particularly in oncology.

GRPR-Targeting Therapies

GRPR Antagonists & Radioligands

Used in molecular imaging and therapy for GRPR-expressing tumors (e.g., neuroendocrine and prostate cancer).

Some experimental agents use radiolabeled peptides to selectively deliver radiation to GRPR-expressing tumors.

Comparison with Docetaxel and Pluvicto

Feature GRPR-Targeting Therapies Docetaxel Pluvicto (177Lu-PSMA-617)

Mechanism Targets GRPR-expressing tumors (often radioligand-based) Chemotherapy that inhibits microtubule function Radioligand therapy targeting PSMA in prostate cancer

Usage Under investigation for imaging & treatment of GRPR+ cancers Standard chemotherapy for prostate, lung, and breast cancer FDA-approved for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)

Toxicity Generally lower systemic toxicity than chemotherapy High toxicity (hair loss, myelosuppression) Moderate (radiation-induced effects)

Effectiveness Early-stage research for cancer treatment Standard first- or second-line treatment for advanced cancer Effective for PSMA+ prostate cancer patients who failed other therapies

Key Takeaways

GRPR-targeted therapy is still under investigation but has potential in prostate and neuroendocrine tumors.

Docetaxel is a traditional chemotherapy with broad applications but high toxicity.

Pluvicto (177Lu-PSMA-617) is a targeted radioligand therapy for PSMA+ prostate cancer, similar in approach to GRPR-targeted radioligands.

Would you like insights on specific GRPR-targeted drugs or ongoing clinical trials?

Is this conversation helpful so far?

Note: If this doesn't help you, then blame my wife.

Good Luck, Good Health and Good Humor.

j-o-h-n

[MateoBeach in reply to j-o-h-n]

TA beats AI on this, hands down (If AI had hands).

[God_Loves_Me in reply to MateoBeach]

100% Agree

[God_Loves_Me]

I hope helps others

Difference from Pluvicto

[God_Loves_Me]

More content

more inform